Earnings Summary

Corbus Pharmaceuticals Holdings, Inc.’s revenue jumped +Inf% since last year same period to $1.35Mn in the Q4 2023. On a quarterly growth basis, Corbus Pharmaceuticals Holdings, Inc. has generated +Inf% jump in its revenue since last 3-months.

Corbus Pharmaceuticals Holdings, Inc.’s net profit jumped 26.71% since last year same period to $-8.02Mn in the Q4 2023. On a quarterly growth basis, Corbus Pharmaceuticals Holdings, Inc. has generated 20.21% jump in its net profits since last 3-months.

Corbus Pharmaceuticals Holdings, Inc.’s net profit margin jumped NaN% since last year same period to -594.27% in the Q4 2023. On a quarterly growth basis, Corbus Pharmaceuticals Holdings, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Corbus Pharmaceuticals Holdings, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.09 - a 53.81% jump from last quarter’s estimates.

Corbus Pharmaceuticals Holdings, Inc.’s earning per share (EPS) estimates for the current year stand at -1.09.

Corbus Pharmaceuticals Holdings, Inc.’s earning per share (EPS) jumped 30.65% since last year same period to -1.81 in the Q4 2023. This indicates that the Corbus Pharmaceuticals Holdings, Inc. has generated 30.65% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Corbus Pharmaceuticals Holdings, Inc.’s return on assets (ROA) stands at -0.6.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Corbus Pharmaceuticals Holdings, Inc.’s return on equity (ROE) stands at -3.42.